INTRODUCTION. In acromegaly, the reported therapeutical efficacy of somatostatin analogs (SSA), i.e. normalization of GH and IGF-1, is 50 -70% (44 -34% in unselected patients). This specific treatment is financially supported by the

CONCLUSION
• In our series, the response to somatostatin analogues evaluated at 3 months was concordant with the response after longer treatment with the same dose in 78.5% of patients for GH and 91.4% for IGF-1.
•When discordances between IGF-1 and random GH occur at 3 months, we suggest a re-evaluation on the same SSA dose. If the discordance persists, a dosage increase should be considered. Before SSA 3 months last evaluation mean ± SD random GH (ng/ml) 14.9 ± 27* 6.5 ± 9.8 5.7 ± 0.6* mean ± SD IGF1 (x ULN) 2.4 ± 1.3* 1.5 ± 0.9 1.4 ± 2. IGF-1 response to SSA
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